Ischemic injury pathways

Ischemic injury pathways, collectively known as the ischemic cascade, encompass the multifaceted molecular and cellular processes initiated by a cessation or significant reduction in blood supply to an organ or tissue [NIH, Wikipedia]. The primary trigger is the depletion of cellular ATP, which leads to the failure of energy-dependent ion pumps, resulting in intracellular calcium overload and the release of excitatory neurotransmitters like glutamate [NIH]. These events activate a series of downstream pathways, including oxidative stress through reactive oxygen species (ROS) generation, mitochondrial dysfunction, and the activation of inflammatory signaling via NF-κB and various cytokines [NIH, MDPI]. Ultimately, these pathways converge to cause cell death through necrosis, apoptosis, or necroptosis, particularly in the penumbra region surrounding the initial site of injury [NIH]. In the context of reperfusion, the reintroduction of oxygen can paradoxically exacerbate damage through the generation of ROS and inflammatory cell infiltration, a phenomenon known as ischemia-reperfusion injury [NIH]. Therapeutic strategies aim to intervene at various nodes within these pathways to provide neuroprotection or cardioprotection, though clinical success has been limited by the multifactorial nature of the injury [NIH]. Drugs such as thrombolytics are used to restore blood flow, while antioxidants and NMDA receptor antagonists have been explored to mitigate specific components of the cascade [NIH]. Despite extensive research, the narrow therapeutic window and the complexity of the interacting pathways remain significant hurdles in drug development [NIH].

Other names

Ischemic cascadeIschemia-reperfusion injury pathwaysIRI pathways

Drugs targeting these pathways act through various mechanisms such as thrombolysis to restore blood flow, scavenging reactive oxygen species, inhibiting excitotoxic signaling, or modulating inflammatory responses [NIH, MDPI].